Saliva level of free 3-methoxy-4-hydroxyphenylglycol in psychiatric outpatients with anxiety

International Clinical Psychopharmacology

Volumn 13, Issue 5, 1998, Pages 213-217

  Yamada, S ^a   Yajima, J ^b   Harano, M ^a   Miki, K ^a   Nakamura, J ^c   Tsuda, A ^b   Shoji, H ^a   Maeda, H ^a   Tanaka, M ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

3 Methoxy 4 hydroxyphenylglycol (MHPG); Alprazolam treatment; Anxiety; Hamilton Anxiety Scale; Saliva

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; ALPRAZOLAM;

ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG MONITORING; FEMALE; GAS CHROMATOGRAPHY; HAMILTON SCALE; HUMAN; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; SALIVA LEVEL;

EID: 0031688119     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199809000-00004     Document Type: Article

References (22)

1. Charney DS, Heninger GR (1986): Abnornal regulation of noradrenergic function in panic disorders. Effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 43:1042-1054.
2. Cooper JR, Bloom FE, Roth RH (1996): Norepinephrine and epinephrine. In: The biochemical basis of neuropharmacology. 7th ed. (JR Cooper, FE Bloom, RH Roth, eds), Oxford University Press, New York. pp. 279-281.
3. Coplan JD, Papp LA, Pine D, Martinez J, Cooper T, Rosenblum LA, et al. (1997): Clinical improvement with fluoxetine therapy and noradrenergic function in patients with panic disorder. Arch Gen Psychiatry 54:643-648.
4. Den-Boer JA, Westenberg HG, Klompmakers AA, van-Lint LE (1989): Behavioral biochemical and neuroendocrine concomitants of lactate-induced panic anxiety. Biol Psychiatry 26:612-622.
5. Drebing CJ, Freedman R, Waldo M, Gerhardt GA (1989): Unconjugated methoxylated catecholamine metabolites in human saliva. Quantitation methodology and comparison with plasma levels. Biomed Chromatgr 3:217-220.
6. Edlund MJ, Swann AC (1989): Continuing in treatment as a form of selection bias. Am J Psychiatry 146:254-256.
7. Garvey MJ, Tollefson GD, Orsulak PJ (1987): Elevations of urinary MHPG in depressed patients with panic attacks. Psychiatry Res 20:183-187.
8. Goenjian AK, Yehuda R, Pynoos RS, Steinberg AM, Tashjian M, Tang RK, et al. (1996): Basal Cortisol, dexamethasone suppression of cortisol, and MHPG in adlescents after the 1988 earthquake in Armania. Am J Psychiatry 153:929-934.
9. Maas JW, Hattox SE, Landis DH, Roth RH (1976): The determination of a brain arteriovenous difference for 3-methox-4-hydroxypheneyl-ethyleneglycol (MHPG). Brain Res 118:167-173.
10. Pliszka SR, Rogeness GA, Medrano MA (1988): DBH, MHPG, and MAO in children with depressive, anxiety, and conduct disorders: relationship to diagnosis and symptom ratings. Psychiatry Res 24:35-44.
11. Pohl R, Ettedgui E, Bridges M, Lycaki H, Jimerson D, Kopin I, Rainey JM (1987): Plasma MHPG levels in lactate and isoproterenol anxiety states. Biol Psychiatry 22:1127-1136.
12. Redmond DE, Katz MM, Maas JW, Swann A, Casper R, Davis JM (1986): Cerebrospinal fluid amine metabolites. Relationships with behavioral measurements in depressed, manic, and health control subjects. Arch Gen Psychiatry 43:938-947.
13. Rosenbaum AH, Schatzberg AF, Jost FA III, Cross PD, Wells LA, Jiang NS, Maruta T (1983): Urinary free cortisol levels in anxiety. Psychosomatics 24:835-837.
14. Roy A, Jimerson DC, Pickar D (1986): Plasma MHPG in depressive disorders and relationship to the dexamethasone suppression test. Am J Psychiatry 143:846-851.
15. Sevy S, Papadimitriou GN, Surmont DW, Goldman S, Mendlewicz J (1989): Noradrenergic function in generalized anxiety disorder, major depressive disorder, and healthy subjects. Biol Psychiatry 25:141-152.
16. Slaap BR, van-Vliet IM, Westenberg HG, Den Boer JR (1996): MHPG and heart rate as correlates of non-response to drug therapy in panic disorder patients. A preliminary report. Psychopharmacology 127:353-358.
17. Stefanescu AM, Popa M, Dumitriu L (1989): Direct assay of 3-methoxy-4-hydroxyphenylglycol (MHPG) in human saliva: a new approach in the assessment of noradrenergic function. Endocrinologie 27:93-96.
18. Sweeney DR, Maas JW, Heninger GR (1978): State anxiety, physical anxiety, and urinary 3-methoxy-4-hydroxyphenyethylene glycol excretion. Arch Gen Psychiatry 35:1418-1423.
19. Uhde TW, Joffe RT, Jimerson DC, Post RM (1988): Normal urinary free cortisol and plasma MHPG in panic disorder: clinical and theoretical implications. Biol Psychiatry 23:575-585.
20. Woods SW, Charney DS, McPherson CA, Gradman AH, Heninger GR (1987): Situational panic attacks. Behavioral, physiologic, and biochemical characterization. Arch Gen Psychiatry 44:365-375.
21. Yajima J, Tsuda A, Katayanagi K, Yamada S: Measurement of saliva free-3-methoxy-4-hydroxyphenylethyleneglycol and effects of stress. J Brain Sci, in press.
22. Yang RK, Yehud R, Holland DD, Kontt PJ (1997): Relationship between 3-methoxy-4-hydroxyphenylglycol and homovanillic acid in saliva and plasma of healthy volunteers. Biol Psychiatry 42:821-826.